Payment overview · 2025
General Payments
$253.68
9 reported records · 5 companies
Healthcare provider profile · identity verified
Vasantha K Perkari, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MATAWAN, NJ · NPI 1215032156
Verified facts
What the public records show
CMS Open Payments records show Vasantha K Perkari, MD received $253.68 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 45.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $114.76 | 45.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $83.88 | 33.1% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.05 | 9.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.72 | 6.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.27 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $253.68 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $114.76 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 22 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1178 | 211 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1098 | 247 |
| Amlodipine Besylate | Amlodipine Besylate | 1033 | 231 |
| Alprazolam | Alprazolam | 774 | 156 |
| Pantoprazole Sodium | Pantoprazole Sodium | 683 | 158 |
| Eliquis | Apixaban | 594 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 587 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 548 | 151 |
| Metoprolol Succinate | Metoprolol Succinate | 543 | 118 |
| Gabapentin | Gabapentin | 497 | 83 |
| Metformin Hcl | Metformin Hcl | 490 | 133 |
| Metoprolol Tartrate | Metoprolol Tartrate | 477 | 72 |
| Losartan Potassium | Losartan Potassium | 459 | 116 |
| Furosemide | Furosemide | 451 | 107 |
| Omeprazole | Omeprazole | 362 | 113 |
| Sertraline Hcl | Sertraline Hcl | 313 | 56 |
| Prednisone | Prednisone | 312 | 170 |
| Potassium Chloride | Potassium Chloride | 296 | 54 |
| Divalproex Sodium | Divalproex Sodium | 263 | 17 |
| Tramadol Hcl | Tramadol Hcl | 261 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 260 | 52 |
| Simvastatin | Simvastatin | 252 | 60 |
| Famotidine | Famotidine | 234 | 57 |
| Mirtazapine | Mirtazapine | 228 | 33 |
| Lisinopril | Lisinopril | 224 | 66 |
| Methylprednisolone | Methylprednisolone | 224 | 167 |
| Azithromycin | Azithromycin | 216 | 148 |
| Meloxicam | Meloxicam | 209 | 66 |
| Carvedilol | Carvedilol | 204 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 203 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 200 | 30 |
| Trazodone Hcl | Trazodone Hcl | 196 | 30 |
| Glimepiride | Glimepiride | 194 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 76 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 171 | 46 |
| Doxycycline Hyclate | Doxycycline Hyclate | 158 | 112 |
| Zolpidem Tartrate | Zolpidem Tartrate | 157 | 35 |
| Xarelto | Rivaroxaban | 147 | 15 |
| Donepezil Hcl | Donepezil Hcl | 144 | 20 |
| Risperidone | Risperidone | 144 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 25 |
| Levetiracetam | Levetiracetam | 138 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 137 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 135 | 100 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 134 | 32 |
| Oxcarbazepine | Oxcarbazepine | 132 | suppressed |
| Finasteride | Finasteride | 127 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 125 | 90 |
| Spironolactone | Spironolactone | 124 | 25 |
| Ozempic | Semaglutide | 119 | 30 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 119 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 118 | 54 |
| Montelukast Sodium | Montelukast Sodium | 118 | 33 |
| Lorazepam | Lorazepam | 114 | 22 |
| Allopurinol | Allopurinol | 111 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 111 | 18 |
| Clonazepam | Clonazepam | 103 | 19 |
| Memantine Hcl | Memantine Hcl | 97 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 97 | 29 |
| Amoxicillin | Amoxicillin | 96 | 74 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 96 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 94 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 15 |
| Synthroid | Levothyroxine Sodium | 94 | 24 |
| Metformin Hcl Er | Metformin Hcl | 91 | 31 |
| Valsartan | Valsartan | 91 | 23 |
| Enalapril Maleate | Enalapril Maleate | 79 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 79 | 23 |
| Sucralfate | Sucralfate | 79 | 13 |
| Baclofen | Baclofen | 77 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 77 | 22 |
| Topiramate | Topiramate | 77 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 37 |
| Alendronate Sodium | Alendronate Sodium | 71 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 23 |
| Nifedipine Er | Nifedipine | 70 | 11 |
| Jardiance | Empagliflozin | 68 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 12 |
| Nystatin | Nystatin | 67 | 32 |
| Ibandronate Sodium | Ibandronate Sodium | 66 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 15 |
| Morphine Sulfate | Morphine Sulfate | 63 | suppressed |
| Pregabalin | Pregabalin | 62 | 14 |
| Clonidine Hcl | Clonidine Hcl | 61 | 19 |
| Lactulose | Lactulose | 60 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 56 | 15 |
| Mupirocin | Mupirocin | 56 | 42 |
| Procrit | Epoetin Alfa | 56 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 56 | suppressed |
| Atenolol | Atenolol | 55 | 17 |
| Bupropion Xl | Bupropion Hcl | 55 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | suppressed |
| Januvia | Sitagliptin Phosphate | 55 | 15 |
| Hydromorphone Hcl | Hydromorphone Hcl | 54 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 53 | 25 |
| Aripiprazole | Aripiprazole | 51 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 51 | 32 |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | suppressed |
| Ezetimibe | Ezetimibe | 50 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | 13 |
| Fluconazole | Fluconazole | 49 | 30 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Latanoprost | Latanoprost | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 43 | 18 |
| Mometasone Furoate | Mometasone Furoate | 43 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 13 |
| Cefuroxime | Cefuroxime Axetil | 41 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 24 |
| Divalproex Sodium Er | Divalproex Sodium | 37 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 36 | suppressed |
| Metronidazole | Metronidazole | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 12 |
| Olanzapine | Olanzapine | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Metolazone | Metolazone | 30 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Nadolol | Nadolol | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 14 |
| Pitavastatin Calcium | Pitavastatin Calcium | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 19 |
| Estradiol | Estradiol | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Colchicine | Colchicine | 22 | 12 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Ursodiol | Ursodiol | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 13 |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Celecoxib | Celecoxib | 19 | suppressed |
| Clozapine | Clozapine | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | 12 |
| Rybelsus | Semaglutide | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Ertapenem | Ertapenem Sodium | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Mesalamine Dr | Mesalamine | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Clarithromycin | Clarithromycin | 16 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Clobazam | Clobazam | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Acetylcysteine | Acetylcysteine | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Desoximetasone | Desoximetasone | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Tetrabenazine | Tetrabenazine | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Zoloft | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $253.68 · 9 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Dexcom G6 Transmitter, ENTRESTO, LEQVIO, OTEZLA, Ozempic, REPATHA, Rybelsus, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error